KINE 101A
Alternative Names: KINE-101ALatest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator Kine Sciences
- Class Antirheumatics; Peptides
- Mechanism of Action Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Chronic inflammatory demyelinating polyradiculoneuropathy
- Preclinical Rheumatoid arthritis
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in USA
- 13 Sep 2024 Phase-I/II clinical trials in Chronic inflammatory demyelinating polyradiculoneuropathy (Treatment-experienced) in South Korea (PO)
- 29 Nov 2023 Preclinical trials in Rheumatoid arthritis in South Korea (PO)